C([N:8]1[C:17](=[O:18])[C:16]2[C:11](=[CH:12][C:13]([O:30][CH3:31])=[C:14]([O:19][CH:20]3[CH2:29][CH2:28][C:23]4([O:27][CH2:26][CH2:25][O:24]4)[CH2:22][CH2:21]3)[CH:15]=2)[N:10]=[CH:9]1)C1C=CC=CC=1.[H][H]>C(O)(=O)C.[Pd]>[O:24]1[C:23]2([CH2:28][CH2:29][CH:20]([O:19][C:14]3[CH:15]=[C:16]4[C:11](=[CH:12][C:13]=3[O:30][CH3:31])[N:10]=[CH:9][NH:8][C:17]4=[O:18])[CH2:21][CH2:22]2)[O:27][CH2:26][CH2:25]127.20 g of 3-benzyl-6-(1,4-dioxa-spiro[4.5]dec-8-yloxy)-7-methoxy-3H-quinazolin-4-one are dissolved in 270 ml glacial acetic acid, combined with 2.70 g palladium on activated charcoal (10%) and hydrogenated at 60° C. until the uptake of hydrogen has ended. Then the glacial acetic acid is distilled off using the rotary evaporator and evaporated off with toluene. The flask residue is mixed with water and made alkaline with saturated sodium hydrogen carbonate solution. The precipitate formed is suction filtered and dried.